Neuropeptides
Volume 44, Issue 3 , Pages 215-224 , June 2010

Pathogenic involvement of neuropeptides in anxiety and depression

Received 14 August 2009 ,Accepted 15 December 2009.

References 

  1. Aguilera G, Subburaju S, Young S, Chen J. The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Prog. Brain Res. 2008;170:29–39
  2. Albert PR, Lemonde S. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist. 2004;10:575–593
  3. Amico JA, Mantella RC, Vollmer RR, Li X. Anxietyand stress responses in femaleoxytocindeficient mice. J. Neuroendocrinol. 2004;16:319–324
  4. Amico JA, Cai HM, Vollmer RR. Corticosterone release inoxytocingene deletion mice following exposure to psychogenic versus non-psychogenicstress. Neurosci. Lett. 2008;442:262–266
  5. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol. 1993;14:76–122
  6. Bacchi F, Mathé AA, Jiménez P, Stasi L, Arban R, Gerrard P, et al. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides. 2006;27:3202–3207
  7. Bailey KR, Pavlova MN, Rohde AD, Hohmann JG, Crawley JH. Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. Pharmacol. Biochem. Behav. 2007;86:8–20
  8. Barr AM, Kinney JW, Hill MN, Lu X, Biros S, Rebek J, et al. A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. Neurosci. Lett. 2006;405:111–115
  9. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. A 6-week randomized, placebo-controlled trial of CP-316, 311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry. 2008;165:617–620
  10. Bissette G, Klimek V, Pan J, Stockmeier C, Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology. 2003;28:1328–1335
  11. Bleickardt CJ, Mullins DE, Macsweeney CP, Werner BJ, Pond AJ, Guzzi MF, et al. Characterization of the V1a antagonist, JNJ-17308616, in rodent models ofanxiety-like behavior. Psychopharmacology. 2009;202:711–718
  12. Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R. Impact of substance P receptorantagonismon the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J. Psychiatry Neurosci. 2004;29:201–208
  13. Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch. Gen. Psychiatry. 2008;65:190–200
  14. Britton KT, Akwa Y, Spina MG, Koob GF. Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides. 2000;21:37–44
  15. Caldwell HK, Lee HJ, Macbeth AH, Young WS. Vasopressin: behavioral roles of an “original” neuropeptide. Prog. Neurobiol. 2008;84:1–24
  16. Campbell A. Attachment, aggression and affiliation: the role ofoxytocinin female social behavior. Biol. Psychol. 2008;77:1–10
  17. Chaki S, Yamaguchi J, Yamada H, Thomsen W, Tran TA, Semple G, et al. ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety. CNS Drug Rev. 2005;11:341–352
  18. Chen J, Young S, Subburaju S, Sheppard J, Kiss A, Atkinson H, et al. Vasopressin does not mediate hypersensitivity of the hypothalamic pituitary adrenal axis during chronic stress. Ann. NY Acad. Sci. 2008;1148:349–359
  19. Chenu F, Guiard BP, Bourin M, Gardier AM. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav. Brain Res. 2006;172:256–263
  20. Cyranowski JM, Hofkens TL, Frank E, Seltman H, Cai HM, Amico JA. Evidence of dysregulated peripheraloxytocinrelease among depressed women. Psychosom. Med. 2008;70:967–975
  21. de Kloet ER, Joëls M, Holsboer F. Stressand the brain: from adaptation to disease. Nat. Rev. Neurosci. 2005;6:463–475
  22. Decaux G, Soupart A, Vasart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–1632
  23. Dempster EL, Burcescu I, Wigg K, Kiss E, Baji I, Gadoros J, et al. Evidenceof anassociationbetween thevasopressin V1b receptorgene(AVPR1B) andchildhood-onsetmood disorders. Arch. Gen. Psychiatry. 2007;64:1189–1195
  24. Dinan TG, Scott LV. Anatomyofmelancholia:focusonhypothalamic–pituitary–adrenalaxisoveractivityand theroleofvasopressin. J. Anat. 2005;207:259–264
  25. Duric V, McCarson KE. Hippocampal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression is decreased in rat models of pain and stress. Neuroscience. 2005;133:999–1006
  26. Eaton K, Sallee FR, Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr. Top. Med. Chem. 2007;7:1645–1659
  27. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids. 2006;31:251–272
  28. Ebner K, Singewald N. Stress-induced release ofsubstance Pin the locus coeruleus modulates cortical noradrenaline release. Naunyn Schmiedebergs Arch. Pharmacol. 2007;376:73–78
  29. Ebner K, Rupniak NM, Saria A, Singewald N. Substance Pin the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl. Acad. Sci. USA. 2004;101:4280–4285
  30. Ebner K, Muigg P, Singewald G, Singewald N. Substance Pin stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann. NY Acad. Sci. 2008;1144:61–73
  31. Ebner K, Sartori SB, Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr. Pharm. Des. 2009;15:1647–1674
  32. Egashira N, Tanoue A, Matsuda T, Koushi E, Harada S, Takano Y, et al. Impaired social interaction and reducedanxiety-related behavior invasopressinV1a receptorknockoutmice. Behav. Brain Res. 2007;178:123–127
  33. Elliott-Hunt CR, Pope RJ, Vanderplank P, Wynick D. Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J. Neurochem. 2007;100:780–789
  34. Figueira ML, Ouakinin S. From psychosomatic to psychological medicine: what’s the future?. Curr. Opin. Psychiatry. 2008;21:412–416
  35. Forster GL, Pringle RB, Mouw NJ, Vuong SM, Watt MJ, Burke AR, et al. Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity. Eur. J. Neurosci. 2008;28:299–310
  36. Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S, et al. Cerebral blood flow changes aftertreatmentofsocialphobiawith theneurokinin-1antagonist GR205171, citalopram, or placebo. Biol. Psychiatry. 2005;58:132–142
  37. Georgescu D, Sears RM, Hommel JD, Barrot M, Bolaños CA, Marsh DJ, et al. The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance. J. Neurosci. 2005;25:2933–2940
  38. Gimpl G, Fahrenholz F. Theoxytocinreceptor system: structure, function, and regulation. Physiol. Rev. 2001;81:629–683
  39. Gorman JM. Comorbiddepression and anxietyspectrumdisorders. Depress. Anxiety. 1996;4:160–168
  40. Greibel G, Stemmelin J, Serradeil-Le Gal C, Soubrie P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr. Pharm. Des. 2005;11:1549–15559
  41. Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A randomized controlled trial of intranasaloxytocinas an adjunct to exposure therapy forsocial anxiety disorder. Psychoneuroendocrinology. 2009;34:917–923
  42. Guiard BP, Przybylski C, Guilloux JP, Seif I, Froger N, De Felipe C, et al. Blockade of substance P (neurokinin1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J. Neurochem. 2004;89:54–63
  43. Gutman AR, Yang Y, Ressler KJ, Davis M. TheroleofneuropeptideYin theexpressionandextinctionoffear-potentiatedstartle. J. Neurosci. 2008;28:12682–12690
  44. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. USA. 2000;97:6079–6084
  45. Hamke M, Herpfer I, Lieb K, Wandelt C, Fiebich BL. Substance Pinduces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor. Brain Res. 2006;1102:135–144
  46. Hammen C. Stressand depression. Annu. Rev. Clin. Psychol. 2005;1:293–319
  47. Heilig M. TheNPYsystem in stress, anxiety and depression. Neuropeptides. 2004;38:213–224
  48. Heilig M, Söderpalm B, Engel JA, Widerlöv E. Centrally administeredneuropeptide Y(NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl). 1989;98:524–529
  49. Heim C, Plotsky PM, Nemeroff CB. Importanceof studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology. 2004;29:641–648
  50. Heinrichs SC, Koob GF. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J. Pharmacol. Exp. Ther. 2004;311:427–440
  51. Hervieu GJ, Cluderay JE, Harrison D, Meakin J, Maycox P, Nasir S, et al. The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur. J. Neurosci. 2000;12:1194–1216
  52. Hindmarch I. Beyondthemonoaminehypothesis: mechanisms, molecules and methods. Eur. Psychiatry. 2002;17(Suppl. 3):294–299
  53. Hobson SA, Bacon A, Elliot-Hunt CR, Holmes FE, Kerr NC, Pope R, et al. Galanin acts as a trophic factor to the central and peripheral nervous systems. Cell Mol. Life Sci. 2008;65:1806–1812
  54. Hodgson RA, Higgins GA, Guthrie DH, Lu SX, Pond AJ, Mullins DE, et al. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154, 526, in rodent models of anxiety and depression. Pharmacol. Biochem. Behav. 2007;86:431–440
  55. Hoge EA, Pollack MH, Kaufman RE, Zak PJ, Simon NM. Oxytocinlevels in social anxiety disorder. CNS Neurosci. Ther. 2008;14:165–170
  56. Hökfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, Diez M. Neuropeptides – an overview. Neuropharmacology. 2000;39:1337–1356
  57. Holsboer F. Thecorticosteroid receptorhypothesis ofdepression. Neuropsychopharmacology. 2000;23:477–501
  58. Huber D, Veinante P, Stoop R. Vasopressin andoxytocinexcite distinct neuronal populations in the central amygdala. Science. 2005;308:245–248
  59. Jüngling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, Clark SD, et al. NeuropeptideS-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in theamygdala. Neuron. 2008;59:298–310
  60. Karlsson RM, Holmes A. Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease. Amino acids. 2006;31:231–239
  61. Kask A, Harro J, von Hörsten S, Redrobe JP, Dumont Y, Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects ofneuropeptide Y. Neurosci. Biobehav. Rev. 2002;26:258–259
  62. Keck ME, Welt T, Müller MB, Landgraf R, Holsboer F. The high-affinity non-peptide CRH1 receptorantagonistR121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. Pharmacopsychiatry. 2003;36:27–31
  63. Keck ME, Kern N, Erhardt A, Unschuld PG, Ising M, Salyakina D, et al. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study forpanicdisorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008;147B:1196–1204
  64. Keen-Rhinehart E, Michopoulos V, Toufexis DJ, Martin EI, Nair H, Ressler KJ, et al. Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol. Psychiatry. 2009;14:37–50
  65. Kehne JH. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol. Disord. Drug Targets. 2007;6:163–168
  66. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, et al. Lack of efficacy of the substance p (neurokinin1 receptor)antagonistaprepitant in the treatment of major depressive disorder. Biol. Psychiatry. 2006;59:216–223
  67. Kennedy AR, Todd JF, Dhillo WS, Seal LJ, Ghatei MA, O’Toole CP, et al. Effect of direct injection of melanin-concentrating hormone into the paraventricular nucleus: further evidence for a stimulatory role in the adrenal axis via SLC-1. J. Neuroendocrinol. 2003;15:268–272
  68. Koob GF. Corticotropin-releasing factor, norepinephrine, andstress. Biol. Psychiatry. 1999;46:1167–1180
  69. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptorantagonistin major depression. Neuropsychopharmacology. 2004;29:385–392
  70. Kuteeva E, Hokefelt T, Wardi T, Ogren SO. Galanin, galanin receptor subtypes and depression-like behavior. Cell Mol. Life Sci. 2008;65:1854–1863
  71. Lage R, Diéguez C, López M. Caffeine treatment regulatesneuropeptideSsystem expression in the rat brain. Neurosci. Lett. 2006;410:47–51
  72. Lage R, González CR, Diéguez C, López M. Nicotine treatment regulatesneuropeptideSsystem expression in the rat brain. Neurotoxicology. 2007;28:1129–1135
  73. Leonard SK, Dwyer JM, Rizzo Sukoff S J, Platt B, Logue SF, Neal SJ, et al. Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl). 2008;197:601–611
  74. Licinio J, O’Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R, et al. Association of a corticotropin-releasing hormone receptor 1haplotypeand antidepressant treatment response in Mexican-Americans. Mol. Psychiatry. 2004;9:1075–1082
  75. Liu Z, Zhu F, Wang G, Xiao Z, Wang H, Tang J, et al. Association of corticotropin-releasing hormone receptor1 geneSNPand haplotype with major depression. Neurosci. Lett. 2006;404:358–362
  76. Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W, et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressantresponsein major depressive disorders. Neurosci. Lett. 2007;414:155–158
  77. Louis C, Cohen C, Depoortère R, Griebel G. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. Neuropsychopharmacology. 2006;31:2180–2187
  78. Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), anantagonistat theneurokinin-2 receptor in various rodent-models. Pharmacol. Biochem. Behav. 2008;89:36–45
  79. Lu X, Barr AM, Kinney JW, Sanna P, Conti B, Behrens MM, et al. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc. Natl. Acad. Sci. USA. 2005;102:874–879
  80. Lu X, Ross B, Sanchez-Alavez M, Zorrilla EP, Bartfai T. Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. Neuropeptides. 2008;42:387–397
  81. Ma QP, Bleasdale C. Modulation of brain stem monoamines and gamma-aminobutyric acid by NK1 receptors in rats. Neuroreport. 2002;13:1809–1812
  82. Maggi CA. The mammalian tachykininreceptors. Gen. Pharmacol. 1995;26:911–944
  83. Makino S, Smith MA, Gold PW. Increased expression of corticotropin-releasing hormone and vasopressin messenger ribonucleic acid (mRNA) in the hypothalamic paraventricular nucleus during repeated stress: association with reduction in glucocorticoid receptor mRNA levels. Endocrinology. 1995;136:3299–3309
  84. Marsteller DA, Gerald CP, Kong R, Cajina M, Craig DA, Swanson CJ. The MCH1 receptor antagonist SNAP 94847 induces sensitivity to dopamine D2/D3 receptor agonists in rats and mice. Eur. J. Pharmacol. 2009;602:66–72
  85. Mechenthaler I. Galanin and the neuroendocrine axes. Cell Mol. Life Sci. 2008;65:1826–1835
  86. Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J. Neurosci. 2004;24:1478–1485
  87. Micale V, Tamburella A, Leggio GM, Mazzola C, Li Volsi V, Drago F. Behavioral effects of saredutant, a tachykinin NK2 receptorantagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol. Biochem. Behav. 2008;90:463–469
  88. Millan MJ, Gobert A, Panayi F, Rivet JM, Dekeyne A, Brocco M, et al. The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats. Int. J. Neuropsychopharmacol. 2008;11:1105–1122
  89. Mistsukawa K, Lu X, et al. Galanin, galanin receptors and drug targets. Cell Mol. Life Sci. 2008;65:1796–1805
  90. Morgan CA, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL, et al. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol. Psychiatry. 2000;47:902–909
  91. Müller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P, et al. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat. Neurosci. 2003;6:1100–1107
  92. Nakajima M, Inui A, Asakawa A, Momose K, Ueno N, Teranishi A, et al. NeuropeptideY producesanxietyviaY2-type receptors. Peptides. 1998;19:359–363
  93. Nemeroff CB, Vale WW. The neurobiology of depression:inroadsto treatment and new drug discovery. Clin. Psychiatry. 2005;66(Suppl. 7):5–13
  94. Nemeroff CB, Widerlöv E, Bissette G, Walléus H, Karlsson I, Eklund K, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 1984;226:1342–1344
  95. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry. 1988;45:577–579
  96. Nemeroff CB, Bissette G, Akil H, Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br. J. Psychiatry. 1991;158:59–63
  97. Nikisch G, Agren H, Eap CB, Czernik A, Baumann P, Mathé AA. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol. 2005;8:403–410
  98. Nomura M, Saito J, Ueta Y, Muglia LJ, Pfaff DW, Ogawa S. Enhanced up-regulation of corticotropin-releasing hormone gene expression in response to restraint stress in the hypothalamic paraventricular nucleus ofoxytocingene-deficient male mice. J. Neuroendocrinol. 2003;15:1054–1061
  99. Ogren SO, Kuteeva E, Hökfelt T, Kehr J. Galaninreceptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs. 2006;20:633–635
  100. Ogren SO, Razani H, Elvander-Tottie E, Kehr J. The neuropeptidegalaninas an in vivo modulator of brain 5-HT1A receptors: possible relevance for affective disorders. Physiol. Behav. 2007;92:172–179
  101. Okamura N, Hashimoto K, Iyo M, Shimizu E, Dempfle A, Friedel S, et al. Gender-specific association of a functional coding polymorphism in theNeuropeptideSreceptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31:1444–1448
  102. Pañeda C, Huitron-Resendiz S, Frago LM, Chowen JA, Picetti R, de Lecea L, et al. NeuropeptideSreinstatescocaine-seeking behavior and increases locomotor activity through corticotropin-releasing factor receptor 1 in mice. J. Neurosci. 2009;29:4155–4161
  103. Phelps EA, LeDoux JE. Contributionsof theamygdalato emotion processing: from animal models to human behavior. Neuron. 2005;48:175–187
  104. Plotsky PM, Thrivikraman KV, Nemeroff CB, Caldji C, Sharma S, Meaney MJ. Long-termconsequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring. Neuropsychopharmacology. 2005;30:2192–2204
  105. Purba J, Hoogendijk W, Hoffman M, Swaab D. Increased numbers of vasopressin- and oxytocin-containing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry. 1996;53:137–143
  106. Rainnie DG, Bergeron R, Sajdyk TJ, Patil M, Gehlert DR, Shekhar A. Corticotrophin releasing factor-induced synaptic plasticity in theamygdalatranslates stress into emotional disorders. J. Neurosci. 2004;24:3471–3479
  107. Raiteri L, Luccini E, Romei C, Salvadori S, Calò G. NeuropeptideSselectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings. Br. J. Pharmacol. 2009;157:474–481
  108. Redrobe JP, Dumont Y, Fournier A, Baker GB, Quirion R. Role ofserotonin(5-HT) in the antidepressant-like properties ofneuropeptide Y(NPY) in the mouse forced swim test. Peptides. 2005;26:1394–1400
  109. Reinscheid RK, Xu YL, Okamura N, Zeng J, Chung S, Pai R, et al. Pharmacological characterization of human and murine neuropeptide s receptor variants. J. Pharmacol. Exp. Ther. 2005;315:1338–1345
  110. Renoldi G, Invernizzi RW. Blockade of tachykinin NK1 receptors attenuates stress-induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal cortex. J. Neurosci. Res. 2006;84:961–968
  111. Reul JM, Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2002;2:23–33
  112. Ribeiro SJ, Teixeira RM, Calixto JB, De Lima TC. Tachykinin NK(3)receptor involvement in anxiety. Neuropeptides. 1999;33:181–188
  113. Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, et al. Anxiolytic-like activity of oxytocin in male mice. behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl). 2006;185:218–225
  114. Ring, R.H., Schechter, L.E., Leonard, S.K., Dwyer, J.M., Platt, B.J., Graf, R., Grauer, S., Pulicicchio, C., Resnick, L., Rahman, Z., Sukoff Rizzo, S.J., Luo, B., Beyer, C.E., Logue, S.F., Marquis, K.L., Hughes, Z.A., Rosenzweig-Lipson, S., 2009. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology (Epub ahead of print).
  115. Rizzi A, Vergura R, Marzola G, Ruzza C, Guerrini R, Salvadori S, et al. NeuropeptideSis a stimulatory anxiolytic agent: a behavioural study in mice. Br. J. Pharmacol. 2008;154:471–479
  116. Rosenkranz MA. Substance Pat the nexus of mind and body in chronic inflammation and affective disorders. Psychol. Bull. 2007;133:1007–1037
  117. Roy M, David NK, Danao JV, Baribault H, Tian H, Giorgetti M. Genetic inactivation of melanin-concentrating hormone receptor subtype 1 (MCHR1) in mice exerts anxiolytic-like behavioral effects. Neuropsychopharmacology. 2006;31:112–120
  118. Sajdyk TJ, Fitz SD, Shekhar A. The role of neuropeptide Y in the amygdala on corticotropin-releasing factor receptor-mediated behavioral stress responses in the rat. Stress. 2006;9:21–28
  119. Sajdyk TJ, Johnson PL, Leitermann RJ, Fitz SD, Dietrich A, Morin M, et al. Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic–adrenal–pituitary axis activity or hyperthermia. J. Neurosci. 2008;28:893–903
  120. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc. Natl. Acad. Sci. USA. 2001;98:1912–1917
  121. Sartori SB, Ebner K, Muigg P, Landgraf R, Singewald N. Differences in substance P neurotransmission between rats with high vs low trait anxiety/depression. J. Neurochem. 2005;94:229
  122. Sawchenko PE, Swanson LW, Grzanna R, Howe PR, Bloom SR, Polak JM. Colocalization ofneuropeptide Yimmunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus. J. Comp. Neurol. 1985;241:138–153
  123. Scantamburlo G, Hansenne M, Fuchs S, Pitchot W, Maréchal P, Pequeux C, et al. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology. 2007;32:407–410
  124. Schmidt ED, Bennekade R, Janszen AW, Tilders FJ. Short stressor induced long-lasting increases of vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult rats. J Neuroendocrinol. 1996;8:703–712
  125. Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, et al. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev. 2005;11:53–68
  126. Shimazaki T, Yoshimizu T, Chaki S. Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders. CNS Drugs. 2006;20:801–811
  127. Simon NG, Guillon C, Fabio K, Heindel ND, Lu SF, Miller M, et al. Vasopressin antagonists as anxiolytics and antidepressants: recent developments. Recent Pat. CNS Drug Discov. 2008;3:77–93
  128. Smith PW, Dawson LA. Neurokinin 3 (NK3) receptor modulators for the treatment of psychiatric disorders. Recent Pat. CNS Drug Discov. 2008;3:1–15
  129. Smith KL, Patterson M, Dhillo WS, Patel SR, Semjonous NM, Gardiner JV, et al. NeuropeptideSstimulatesthehypothalamo–pituitary–adrenalaxisandinhibitsfood intake. Endocrinology. 2006;147:3510–3518
  130. Smith DG, Hegde LG, Wolinsky TD, Miller S, Papp M, Ping X, et al. The effects of stressful stimuli and hypothalamic–pituitary–adrenal axis activation are reversed by the melanin-concentrating hormone 1 receptor antagonist SNAP 94847 in rodents. Behav. Brain Res. 2009;197:284–291
  131. Sørensen G, Lindberg C, Wörtwein G, Bolwig TG, Woldbye DP. Differentialroles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J. Neurosci. Res. 2004;77:723–729
  132. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, et al. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J. Pharmacol. Exp. Ther. 2001;299:449–458
  133. Stout SC, Owens MJ, Nemeroff CB. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic–pituitary–adrenal axis activity by stress and chronicantidepressanttreatment. J. Pharmacol. Exp. Ther. 2002;300:1085–1092
  134. Swanson CJ, Blackburn TP, Zhang X, Zheng K, Xu ZQ, Hökfelt T, et al. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc. Natl. Acad. Sci. USA. 2005;102:17489–17494
  135. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, et al. The vasopressin V1b receptor critically regulates hypothalamic–pituitary–adrenal axis activity under both stress and resting conditions. J. Clin. Invest. 2004;113:302–309
  136. Tortorella C, Neri G, Nussdorfer GG. Galaninin the regulation of the hypothalamic–pituitary–adrenal axis. Int. J. Mol. Med. 2007;19:639–647
  137. Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, Vezzani A, et al. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur. J. Neurosci. 2003;18:143–148
  138. Unschuld PG, Ising M, Erhardt A, Lucae S, Kohli M, Kloiber S, et al. Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder. J. Affect. Disord. 2008;105:177–184
  139. van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen-Sierevogel AC, Wiegant VM, van der Velde EA, et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology. 1997;17:284–292
  140. van West D, Del-Favero J, Aulchenko Y, Oswald P, Souery D, Forsgren T, et al. A majorSNPhaplotype of the argininevasopressin1B receptor protects against recurrent major depression. Mol. Psychiatry. 2004;9:287–292
  141. Vitale G, Filaferro M, Ruggieri V, Pennella S, Frigeri C, Rizzi A, et al. Anxiolytic-like effect ofneuropeptideSin the rat defensive burying. Peptides. 2008;29:2286–2289
  142. Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress. 2004;7:75–83
  143. Walker MW, Wolinsky TD, Jubian V, Chandrasena G, Zhong H, Huang X, et al. The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity. J. Pharmacol. Exp. Ther. 2009;328:900–911
  144. Watson S, Gallagher P, Ferrier IN, Young AH. Post-dexamethason arginine vasopressin levels in patients with severe modd disorders. J. Psychiatr. Res. 2006;40:353–359
  145. Weiss JM, Boss-Williams KA, Moore JP, Demetrikopoulos MK, Ritchie JC, West CH. Testing the hypothesis that locus coeruleus hyperactivity produces depression-related changes viagalanin. Neuropeptides. 2005;39:281
  146. Womack MD, Barrett-Jolley R. Activation of paraventricular nucleus neurones by the dorsomedial hypothalamus via a tachykinin pathway in rats. Exp. Physiol. 2007;92:671–676
  147. Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, et al. NeuropeptideS: neuropeptidepromotingarousaland anxiolytic-like effects. Neuron. 2004;43:487–497
  148. Xu YL, Gall CM, Jackson VR, Civelli O, Reinscheid RK. Distribution ofneuropeptideS receptor mRNA and neurochemical characteristics ofneuropeptideS-expressing neurons in the rat brain. J. Comp. Neurol. 2007;500:84–102
  149. Yehuda R, Brand S, Yang RK. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol. Psychiatry. 2006;59:660–663
  150. Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R, et al. Genetic variation in humanNPYexpression affects stress response and emotion. Nature. 2008;452:997–1001

PII: S0143-4179(09)00153-X

doi: 10.1016/j.npep.2009.12.014

Neuropeptides
Volume 44, Issue 3 , Pages 215-224 , June 2010

Article Tools